219 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Rank Status Study
1 Recruiting NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
2 Not yet recruiting Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
Conditions: Lung Adenocarcinoma;   Breast Adenocarcinoma;   Pancreatic Ductal Adenocarcinoma
Intervention: Other: their will be no intervention in any of the groups, the study is retrospective
3 Unknown  Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
4 Recruiting Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Conditions: Lung Adenocarcinoma;   Brain Metastases
Interventions: Drug: erlotinib;   Drug: pemetrexed;   Drug: cisplatin
5 Completed Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Conditions: Non-small-cell Lung Cancer;   Squamous Cell Carcinoma;   Adenocarcinoma of the Lung
Interventions: Drug: AXL1717;   Drug: Docetaxel
6 Recruiting Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
7 Unknown  The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
8 Not yet recruiting A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
9 Completed A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab;   Other: Placebo;   Drug: Platinum Containing Doublet
10 Not yet recruiting Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
Conditions: Non-small Cell Lung Cancer Stage I;   Lung Adenocarcinoma
Interventions: Procedure: patients undergo cVATS segmentectomy;   Procedure: Patients undergo cVATS lobectomy
11 Completed Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib along with cetuximab
12 Completed Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Condition: Adenocarcinoma of the Lung
Interventions: Drug: Vintafolide;   Drug: Etarfolatide
13 Recruiting Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Condition: KIF5B-RET-Positive Adenocarcinoma of the Lung
Intervention: Drug: Lenvatinib
14 Unknown  Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
15 Active, not recruiting Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: Hsp90 inhibitor AUY922;   Other: laboratory biomarker analysis;   Procedure: needle biopsy;   Genetic: mutation analysis;   Other: pharmacological study
16 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: acetylsalicylic acid;   Other: laboratory biomarker analysis
17 Completed Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Conditions: Pneumonic-type Adenocarcinoma (P-ADC);   Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Intervention: Drug: Gefitinib
18 Active, not recruiting Erlotinib With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
19 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent docetaxel;   Drug: Arm B: Combination of ganetespib and docetaxel
20 Completed Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: sorafenib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years